Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records for Cagrilintide

7 records for Cagrilintide, of which 1 are published trials.

Showing 0 records on this page

Records

7 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
CAGRI-PH2-DOSEFINDCagrilintidePhase 2ReportedDose-finding7062021Moderate
CAGRI-PH2-DOSEFIND-PKprogramme recordCagrilintidePhase 1ReportedPhase 1 ascending dose2021Very low
CAGRI-PH2-DOSEFIND-RENAL-IMPprogramme recordCagrilintidePhase 1ReportedPhase 1 ascending dose2021Very low
CAGRI-PH2-DOSEFIND-HEPATIC-IMPprogramme recordCagrilintidePhase 1ReportedPhase 1 ascending dose2021Very low
CAGRI-PH2-DOSEFIND-DDIprogramme recordCagrilintidePhase 1ReportedRandomised crossover2021Very low
AMY-PH1-ORALprogramme recordCagrilintidePhase 1ReportedPhase 1 ascending doseVery low
AMY-PH1B-SCprogramme recordCagrilintidePhase 1ReportedPhase 1 ascending doseVery low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.